Any upgrade to animal rights should be welcome Tuckahoe, N.Y.: How sad that the Daily News chose to take aim at a court decision that might have significantly helped the plight of animals, who are the ...

Quest Diagnostics has signed up to offer a blood test that can help diagnose Alzheimer’s disease, following its FDA clearance earlier this year. | The Lumipulse G blood test measures the ratio between ...

Quest will offer the first FDA-approved blood test to help detect Alzheimer’s-related amyloid pathology in patients with ...

H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G sTREM2 assay for the fully automated LUMIPULSE® G immunoassay analyzers ...

Evidence of Lumipulse's efficacy included data from the Global Alzheimer's Platform Foundation's Bio-Hermes-001 study, of which both Ixico and Fujirebio are partners.

GENT, Belgium & MALVERN, Pa. & TOKYO, June 04, 2025--H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G sTREM2 assay for the ...

Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G sTREM2 Assay for Research Use Only H.U. Group Holdings Inc. and its wholly-owned subsidiary ...

Last week, the US Food & Drug Administration approved marketing for a blood test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, developed by the Pennsylvania-based biotechnology company ...

Cleared for marketing on Wednesday, the Lumipulse G pTau217/ß-Amyloid 1-42 plasma ratio test identifies amyloid plaques, one of the key hallmarks of Alzheimer’s, in adults aged 55 and older who ...

The Lumipulse blood test became the first “in vitro diagnostic device” to be endorsed by the U.S. Food and Drug Administration, which cleared it earlier this month as a new tool in diagnosing ...

According to the FDA’s press release, the Lumipulse blood test works by measuring the amount of pTau 217 and beta-amyloid 1-42 in the plasma of the blood.